COGT

In a report released on August 9, David Nierengarten from Wedbush reiterated a Buy rating on Cogent Biosciences (COGT - Research Report), with a price target of $20.00. The company's shares closed last Friday at $14.13.According to TipRanks, Nierengarten is a 5-star analyst with an average return of 18.6% and a 47.24% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Epizyme, Intellia Therapeutics, and Cogent Biosciences.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cogent Biosciences with a $19.25 average price target, implying a 36.23% upside from current levels.
https://www.tipranks.com/news/blurbs/cogent-biosciences-cogt-receives-a-buy-from-wedbush?utm_source=advfn.com&utm_medium=referral